
|Articles|February 1, 2004
Acne treatment comes of age
Waikoloa, Hawaii - The large, multicenter B.E.S.T. (Balancing Efficacy, Speed and Tolerability) clinical trial provides real-world data, reinforcing the conclusion that tazarotene 0.1 percent cream (Tazorac for acne) applied once daily in the evening is a highly and rapidly effective, well-tolerated treatment for acne vulgaris, said Dina N. Anderson, M.D., at the annual Hawaii Dermatology Seminar in January.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















